Hirotaka Nakayama

Hirotaka Nakayama

Auto-generated profile, based on publicly available information

Hirotaka Nakayama

Department of Surgery, Hiratsuka Kyosai Hospital, Hiratsuka, Kanagawa, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NONaoyoshi Onoda
Naoyoshi Onoda
ISIwao Sugitani
Iwao Sugitani
KIKen-ichi Ito
Ken-ichi Ito
ASAkifumi Suzuki
Akifumi Suzuki
THTakuya Higashiyama
Takuya Higashiyama
SSShinichi Suzuki
Shinichi Suzuki
Background: The tumor–node–metastasis (TNM) classification system to categorized anaplastic thyroid cancer (ATC) was revised. Methods: The revised system was evaluated using a large database of ATC patients. Results: A total of 757 patients were analyzed. The proportion and median overall survival values (OS: months) for each T category were T1 (n = 8, 1.1%, 12.5), T2 (n = 43, 5.7%, 10.9), T3a (n = 117, 15.5%, 5.7), T3b (n = 438, 57.9%, 3.9), and T4 (n = 151, 19.9%, 5.0). The OS of the N0 and N1 patients were 5.9 and 4.3, respectively (log-rank p < 0.01). Sixty-three (58.3%) patients migrated from stage IV A to IV B by revision based on the existence of nodal involvement and 422 patients (55.7%) were stratified into stage IV B, without a worsening of their OS (6.1), leaving 45 patients (5.9%) in stage IV A with fair OS (15.8). The hazard ratios for the survival of the patients of stage IV B compared to stage IV A increased from 1.1 to 2.1 by the revision. No change was made for stage IV C (n = 290, 38.8%, 2.8). Conclusion: The revised TNM system clearly indicated the prognoses of ATC patients by extracting rare patients with fair prognoses as having stage IV A disease and categorized many heterogeneous patients in stage IV B.

1 September 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NWNobuyuki Wada
Nobuyuki Wada
KSKiminori Sugino
Kiminori Sugino
TMTakashi Mimura
Takashi Mimura
MNMitsuji Nagahama
Mitsuji Nagahama
WKWataru Kitagawa
Wataru Kitagawa
KIKoichi Ito
Koichi Ito
To examine the outcomes and risk factors in pediatric differentiated thyroid carcinoma (DTC) patients who were defined as TNM stage I because some patients develop disease recurrence but treatment strategy for such stage I pediatric patients is still controversial.

2 November 2007
Verified
Journal Article
Closed access
HNHirotaka Nakayama
Hirotaka Nakayama
AYAkira Yoshida
Akira Yoshida
YNYoshiyasu Nakamura
Yoshiyasu Nakamura
HHHiroyuki Hayashi
Hiroyuki Hayashi
YMYouhei Miyagi
Youhei Miyagi
TIToshio Imada
Toshio Imada

1 September 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
TYTatsuya Yoshida
Tatsuya Yoshida
NSNobuyasu Suganuma
Nobuyasu Suganuma
SSShinya Sato
Shinya Sato
STSoji Toda
Soji Toda
HNHirotaka Nakayama
Hirotaka Nakayama
DHDaisuke Hoshino
Daisuke Hoshino
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive cancer types; however, the molecular mechanism contributing to the aggressive characteristics remain unclear. Membrane type 1 matrix metalloproteinase (MT1-MMP) plays an important role in cancer invasion and has been associated with a poor prognosis in various malignant neoplasms. In this study, we investigated the relationship between MT1-MMP expression and the proliferation and invasion of ATC cells, along with the association with clinicopathologic factors in patients with ATC. Suppression of MT1-MMP reduced the proliferation and invasion of ATC cells, and suppressed ERK activity, indicating a role in cancer cell proliferation in collagen matrix culture conditions. The expression of MT1-MMP was detected in 29 of 34 (85.3%) surgical specimens from ATC patients. In addition, the expression of MT1-MMP in the tumor lesion was higher than that of normal and stromal tissues. Collectively, these results suggest that elevated MT1-MMP expression plays a role in the pathogenesis of ATC, which may promote its aggressive characteristics such as proliferation and invasion, highlighting a potential new therapeutic target.

27 February 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HIHitoshi Inari
Hitoshi Inari
NSNobuyasu Suganuma
Nobuyasu Suganuma
KKKae Kawachi
Kae Kawachi
TYTatsuya Yoshida
Tatsuya Yoshida
TYTakashi Yamanaka
Takashi Yamanaka
MMMunetaka Masuda
Munetaka Masuda
In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer. EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High-level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.

7 February 2020 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
HYHaruhiko Yamazaki
Haruhiko Yamazaki
TYTomoyuki Yokose
Tomoyuki Yokose
HHHiroyuki Hayashi
Hiroyuki Hayashi
HIHiroyuki Iwasaki
Hiroyuki Iwasaki
SOSachie Osanai
Sachie Osanai
MMMunetaka Masuda
Munetaka Masuda